Resource impact report

Resource impact
Published: 18 January 2024

www.nice.org.uk

This guidance is a review of TA693 in which olaparib plus bevacizumab was recommended for use within the Cancer Drugs Fund.

Olaparib with bevacizumab is recommended, within its marketing authorisation, for maintenance treatment of high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer in adults whose cancer:

- has completely or partially responded after first-line platinum-based chemotherapy with bevacizumab
- is advanced (International Federation of Gynecology and Obstetrics [FIGO] stages 3 and 4) and
- is homologous recombination deficiency (HRD) positive (defined as having either a BRCA1 or BRCA2 mutation, or genomic instability).

Currently around 500 people per year have treatment with olaparib plus bevacizumab in the Cancer Drugs Fund. The percentage of people having treatment with olaparib plus bevacizumab is not expected to change when the drug moves into routine commissioning.

Table 1 People expected to have treatment with olaparib plus bevacizumab (after adjusting for population growth)

Year	2023/24	2024/25	2025/26	2026/27	2027/28
Number of people having treatment with pembrolizumab plus chemotherapy	500	500	510	510	520

The cost of HRD tests, which have been funded by the company will fall into routine commissioning and the company will no longer fund these tests. The template includes a cost per test of £4,010. This is based on the total cost of the number of people tested and this cost then being applied to the number of people having first-line platinum-based chemotherapy plus bevacizumab. An illustrative lab time per test of 60 minutes is included in the template but users are encouraged to update this based on local information.

This report is supported by a local template because olaparib is available with a discount to the list price that is commercial in confidence. Users can enter the discounted price into the template to calculate the impact to routine commissioning of the drug moving out of the CDF. The template has been populated where information is available to assess the capacity impact. Olaparib plus bevacizumab is commissioned by NHS England, providers are NHS hospital trusts.